The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

[1]  C. Sternberg,et al.  First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. , 2015 .

[2]  S. Groshen,et al.  Eribulin in advanced urothelial cancer (AUC) patients (pts): A California Cancer Consortium trial—NCI/CTEP 7435. , 2015 .

[3]  D. Bajorin,et al.  First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. , 2015, Hematology/oncology clinics of North America.

[4]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[5]  David C. Smith,et al.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma , 2014, Cancer.

[6]  T. H. Klotz,et al.  Prospective randomized double‐blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO‐AB 31/05) , 2014, BJU international.

[7]  David C. Smith,et al.  Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma , 2014, Investigational New Drugs.

[8]  J. Machiels,et al.  Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB) , 2013, Oncology.

[9]  A. Eisen,et al.  Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. , 2013, The Lancet. Oncology.

[10]  M. Dimopoulos,et al.  Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Oh,et al.  Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract , 2013, Cancer Chemotherapy and Pharmacology.

[12]  J. Bellmunt,et al.  New therapeutic challenges in advanced bladder cancer. , 2012, Seminars in oncology.

[13]  J. Carles,et al.  Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. , 2012, European journal of cancer.

[14]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Sonpavde,et al.  Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. , 2012, Clinical genitourinary cancer.

[16]  J. Maroto,et al.  Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Sonpavde,et al.  Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  D. Mavroudis,et al.  Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) , 2012, Cancer Chemotherapy and Pharmacology.

[19]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Sonpavde,et al.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Cynthia S. Johnson,et al.  Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Sonpavde,et al.  First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Lester,et al.  Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature. , 2010, European journal of cancer care.

[24]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.

[25]  M. Dimopoulos,et al.  Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment , 2008, Oncology.

[26]  R. Gaafar,et al.  Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. , 2008, Urologic oncology.

[27]  S. Awasthi,et al.  Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium , 2008, Investigational New Drugs.

[28]  D. Amadori,et al.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.

[29]  T. Ecke,et al.  Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. , 2006, Oncology reports.

[30]  David J. Arenillas,et al.  NovelFam3000 – Uncharacterized human protein domains conserved across model organisms , 2006, BMC Genomics.

[31]  M. Dimopoulos,et al.  The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma , 2006, Cancer.

[32]  J. Hainsworth,et al.  Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium , 2005, Cancer.

[33]  V. Lorusso,et al.  Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium. , 2005, Oncology reports.

[34]  A. Bamias,et al.  Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. , 2004, Urology.

[35]  M. May,et al.  Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium , 2004, International journal of urology : official journal of the Japanese Urological Association.

[36]  J. Carles,et al.  Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract , 2003, Cancer.

[37]  D. Pectasides,et al.  Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  H. Gurney,et al.  Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  B. Redman,et al.  Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  F. Selvaggi,et al.  Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. , 2000, The Journal of urology.

[42]  J. Carles,et al.  Carboplatin-Gemcitabine Treatment of Patients with Transitional Cell Carcinoma of the Bladder and Impaired Renal Function , 2000, Oncology.

[43]  W. Oh,et al.  Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  L. Crinò,et al.  Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  I. Tannock,et al.  Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Mazumdar,et al.  Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Neuberg,et al.  Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Ravaud,et al.  Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. , 2015, European journal of cancer.

[49]  D. Schrijvers,et al.  Carboplatin and gemcitabine in patients with advanced and/or metastatic urothelial cancers: A phase II study , 2011 .

[50]  J. Baselga,et al.  A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. , 2001, European journal of cancer.

[51]  P. Maisonneuve,et al.  Pancreatico-biliary malignancy: prevalence and risk factors. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.